Tiotropium
- Atc Codes:R03BB04
- CAS Codes:139404-48-1
- PHARMGKB ID:139404-48-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Spiriva; Belgium: Spiriva; Bulgaria: Spiriva; Cyprus: Spiriva; Czech Republic: Spiriva; Denmark: Spiriva; Finland: Spiriva; France: Spiriva; Germany: Spiriva; Greece: Spiriva;Hungary: Spiriva; Ireland: Spiriva; Italy: Spiriva; Latvia: Spiriva; Lithuania: Spiriva; Netherlands: Spiriva; Poland: Spiriva; Portugal: Spiriva; Romania: Spiriva; Slovakia: Spiriva; Slovenia: Spiriva; Spain: Spiriva; Sweden: Spiriva; UK: Spiriva.
North America
Canada: Spiriva; USA: Spiriva.
Latin America
Argentina: Spiriva; Brazil: Spiriva; Mexico: Spiriva.
Asia
Japan: Spiriva.
Drug combinations
Chemistry
Tiotropium Bromide: C~19~H~22~BrNO~4~S~2~. Mw: 472.42. 6β,7β-Epoxy-3β-hydroxy-8-methyl-1αH,5αH-tropanium bromide, di-2-thienylglycolate. CAS-139404-48-1.
Pharmacologic Category
Anticholinergic Agents; Antimuscarinics/Antispasmodics. (ATC-Code: R03BB04).
Mechanism of action
Blocks action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation.
Therapeutic use
Maintenance treatment of bronchospasm associated with COPD (bronchitis and emphysema).
Pregnancy and lactiation implications
Adverse events (fetal loss, decreased birth weights, delayed sexual maturation) observed in some animal studies. There are no adequate, well-controlled studies in pregnant women. Use only when expected benefit to mother outweighs potential risk to fetus. Excretion in breast milk unknown (use with caution in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to tiotropium, atropine or its derivatives, including ipratropium, or any component of the formulation (contains lactose).
Warnings and precautions
Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents. Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) reported. Not indicated for initial (rescue) treatment of acute episodes of bronchospasm. Use with caution in narrow-angle glaucoma, in myasthenia gravis, in prostatic hyperplasia or bladder neck obstruction, and in moderate-to-severe renal impairment. Avoid inadvertent instillation of powder into the eyes.